OncoMatch/Clinical Trials/NCT06907342
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
Is NCT06907342 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies FOLFOX or FOLFIRI for tumor, colorectal.
Treatment: FOLFOX or FOLFIRI — COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
Histologically confirmed pMMR/MSS adenocarcinoma originating from the colon or rectum
Excluded: MMR deficient
Patient has metastatic MMR deficient/MSI adenocarcinoma
Excluded: DPYD partial or complete deficiency
Partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antitumoural treatment
Exception: hormonal substitutive treatment is allowed
Antitumoural treatment ≤ 30 days before inclusion. Hormonal substitutive treatment is allowed
Lab requirements
Blood counts
Acceptable organ function (defined in publicly available protocol)
Kidney function
Acceptable organ function (defined in publicly available protocol)
Liver function
Acceptable organ function (defined in publicly available protocol)
Cardiac function
Preexisting significant cardiovascular disease including uncontrolled/unstable or symptomatic angina, uncontrolled atrial or ventricular arrythmias, LVEF known to be < 40% or symptomatic congestive heart failure; Stroke (including TIA) or acute myocardial infarction within 6 months before the first dose of study treatment
Acceptable organ function (defined in publicly available protocol); Preexisting significant cardiovascular disease including uncontrolled/unstable or symptomatic angina, uncontrolled atrial or ventricular arrythmias, LVEF known to be < 40% or symptomatic congestive heart failure; Stroke (including TIA) or acute myocardial infarction within 6 months before the first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify